Previous studies show that prostate cancer cells depleted of RNase L were resistant to apoptosis by the combined treatment of anti-cancer drugs, TNF-related apoptosis-inducing ligand (TRAIL) and Camptothecin, suggesting that mutations in RNase L may render tumor cells refractory to cell death by conventional therapies [16]. The gene discussed is TNFSF10; the disease is cancer.